Related Experiment Videos
Effects of sandostatin and castration on pancreatic carcinogenesis in rats and hamsters
M Meijers1, R A Woutersen, A van Garderen-Hoetmer
1Department of Biological Toxicology, TNO Toxicology and Nutrition Institute, The Netherlands.
Abstract:
The effects of treatment with the somatostatin analogue Sandostatin, separately and in combination with surgical castration, on the development of azaserine-induced lesions in rat pancreas and N-nitrosobis(2-oxopropyl)amine (BOP)-induced lesions in hamster pancreas were investigated. The animals were divided in 4 groups and treated as follows: (a) controls, injected s.c. with saline solution (0.9% NaCl); (b) orchiectomy directly after the last treatment with carcinogen; (c) Sandostatin (SMS 201-995) subcutaneously; (d) orchiectomy followed by treatment with Sandostatin. No significant suppressive effects on plasma EGF or IGF-I concentrations were noted after Sandostatin treatment, but plasma gastrin levels decreased slightly in the rats, not in the hamsters. In rats, Sandostatin treatment enhanced rather than inhibited growth of acidophilic atypical acinar cell nodules. In hamster pancreas, by contrast, Sandostatin inhibited the development of putative pre-neoplastic ductular lesions. There was no interaction between treatment with Sandostatin and surgical castration. It was concluded that Sandostatin, when administered prophylactically, has an inhibitory effect on the growth of putative pre-neoplastic ductular, but not acinar, lesions.
Insights
Sandostatin (somatostatin analogue) showed a dual effect on pancreatic lesions. It inhibited pre-neoplastic ductular lesions in hamsters but enhanced atypical acinar cell nodules in rats.
Area of Science:
- Gastroenterology and Hepatology
- Oncology
- Endocrinology
Background:
- Pancreatic cancer remains a significant health challenge with limited therapeutic options.
- Investigating novel therapeutic agents like somatostatin analogues is crucial for early intervention.
- Understanding the impact of Sandostatin on pre-neoplastic lesions is key to its potential use in cancer prevention.
Purpose of the Study:
- To evaluate the prophylactic effects of Sandostatin, alone and with castration, on chemically induced pancreatic lesions in rats and hamsters.
- To determine Sandostatin's influence on specific pre-neoplastic lesion types (ductular vs. acinar).
- To assess potential interactions between Sandostatin and surgical castration in modulating lesion development.
Main Methods:
- Azaserine-induced pancreatic lesions in rats and N-nitrosobis(2-oxopropyl)amine (BOP)-induced lesions in hamsters were studied.
- Animals were assigned to four groups: control, orchiectomy, Sandostatin treatment, and combined orchiectomy and Sandostatin treatment.
- Plasma levels of EGF, IGF-I, and gastrin were monitored; lesion development was histologically assessed.
Main Results:
- Sandostatin did not significantly alter plasma EGF or IGF-I levels but slightly decreased gastrin in rats.
- In rats, Sandostatin enhanced the growth of atypical acinar cell nodules.
- Conversely, Sandostatin inhibited the development of putative pre-neoplastic ductular lesions in hamsters; no interaction with castration was observed.
Conclusions:
- Sandostatin exhibits a differential effect on pancreatic pre-neoplastic lesions, inhibiting ductular lesions but not acinar lesions.
- Prophylactic administration of Sandostatin may hold potential for preventing specific types of pancreatic pre-neoplastic lesions.
- Further research is needed to elucidate the mechanisms underlying Sandostatin's site-specific effects on pancreatic lesion development.